Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q2 2025 vs. Q1 2025
How the institutions holding Gain Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 33 | 35 | +2 |
| Shares | 2.81M | 3.79M | +977.2K (+34.8%) |
| Value | $5.07M | $6.49M | +$1.42M (+28.1%) |
New holders (6)
Institutions that held Gain Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 94,000 | $169.2K | 0.00% |
| Virtu Financial LLC | 23,801 | $43.0K | 0.00% |
| Gsa Capital Partners LLP | 12,756 | $23.0K | 0.00% |
| Group One Trading, L.P. | 6,401 | $11.5K | 0.00% |
| Raymond James Financial Inc | 2,300 | $4.14K | 0.00% |
| State of Wyoming | 1,194 | $2.15K | 0.00% |
Sold out (4)
Institutions that held Gain Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Quadrature Capital Ltd | 20,154 | $38.3K |
| Two Sigma Securities, LLC | 14,355 | $27.4K |
| Sprott Inc. | 14,000 | $26.7K |
| FMR LLC | 80 | $154 |